Seeking Alpha

Affymax (AFFY +8.9%) wins backing from an FDA advisory panel for its peginesatide anemia drug,...

Affymax (AFFY +8.9%) wins backing from an FDA advisory panel for its peginesatide anemia drug, which competes with a rival drug from Amgen (AMGN). AFFY shares jumped 20%-plus on Monday when briefing documents related to today's meeting were released; trading has been halted since early this afternoon.
From other sites
Comments (1)
  • InvestorProdigy
    , contributor
    Comments (8) | Send Message
     
    Classic Shakeout before the approval. Some hedge funds got stocks at very cheap prices.
    27 Mar 2012, 01:56 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs